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Abstract: Meta-analysis of multi-arm trials has been used increasingly in recent years. The aim of meta-analysis for 
multi-arm trials is to combine evidence from all possible similar studies. In this paper we propose normal approximation 
models by using empirical logistic transform to compare different treatments in multi-arm trials, allowing studies of both 
direct and indirect comparisons. Additionally, a hierarchical structure is introduced in the models to address the problem 
of heterogeneity among different studies. The proposed models are performed using the data from 31 randomized clinical 
trials (RCTs) which determine the efficacy of antiplatelet therapy in maintaining vascular patency.  
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1. INTRODUCTION  
  Most meta-analysis has focused on summarising of 
treatment effect measures based on comparisons of two 
treatments. Some meta-analysis data sets contain information 
on more than two treatments comparing evidence of multi-
arm trials comparisons. This type of data is called Multi-arm 
trials  in this paper although some authors call it mixed 
treatment comparison (MTC). Higgins and Whitehead [1] 
presented a random effect meta-analysis for binary data and 
introduced an idea of ‘borrowing strength’ from indirect 
comparison. They considered using the general parameter 
approach and the exact binomial approach to estimate 
parameters of interest in a meta-analysis. Lu and Ades [2] 
proposed a Bayesian hierarchical model using the Markov 
Chain Monte Carlo to represent meta-analysis of multi-arm 
trials. Inconsistency in multi-arm trials evidence structure 
was examined by Lu and Ades [3]. They performed a 
Bayesian hierarchical model with fixed effects or random 
effects for fitting multi-arm trials under the assumption that 
the available evidence sources were consistent in estimating 
all treatment contrasts.  
  In meta-analysis for comparing two treatments, we 
usually collected all the studies providing information on 
comparing those two treatments directly. However some 
studies in multi-arm trials give a useful information on 
indirect comparison in a situation where the treatments have 
not been directly compared. Thus, there are two types of 
treatment comparisons in meta-analysis of multi-arm trials: 
one is to compare two treatments directly, the other is to use 
information from indirect comparisons. For example, from 
antiplatelet data given in Table 2, there are three groups of 
studies available: treatments A, B and C; the control group 
of the meta-analysis is treatment C, studies in group GAB 
compare treatment A versus B, studies in group GBC compare 
treatment B versus C, and studies in group GCA  compare 
treatment  C versus A and our aim is to compare treatment A  
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versus B. The studies in group GBC and GCA then provide the 
indirect comparison for treatment A versus B. Later in this 
paper, we will blur the concept between direct and indirect 
comparisons since our model can actually give estimate of 
the treatment effect between any two arms of all treatments 
involved in the multi-arm trials. 
  The direct and indirect comparisons for RCTs in a meta-
analysis have been expressed by several authors [2-6]. In this 
paper we propose a normal approximation model based on 
the empirical logistic transform. There are at least two 
advantages comparing to other methods: (1) the proposed 
empirical log-odds ratio models exclude the trial effects and 
then it will give an unbiased estimate for treatment effect 
while the other methods may give a biased estimates in some 
circumstances (see for example the discussion on page 59 in 
[7]); (2) The computation is very efficient and fast. The 
method has been used for the systematic reviews of 
antiplatelet trialists’ collaboration [8] which investigates the 
efficacy of antiplatelet therapy in maintaining vascular 
patency in various categories of patients. The paper is 
organized as follows. We begin by introducing the data 
structure of multi-arm trials and performing empirical log-
odds and empirical log-odds ratio models in Section 2.1. The 
maximum likelihood method is illustrated in Section 2.2. 
The last section concludes the ideas of this paper and gives 
some comments.  
2. METHODOLOGY  
  In this section we shall propose our ideas of empirical 
log-odds and empirical log-odds ratio models through the 
antiplatelet data. Clinically, after coronary artery 
revascularisation of patients, whether by coronary artery 
bypass grafting or by percutaneous transluminal coronary 
angioplasty, angiographic studies show substantial rates of 
re-occlusion [9]. Experimental and clinical evidence suggests 
that antiplatelet therapy may help prevent vascular graft or 
arterial occlusions, particularly during the period soon after 
vascular procedures, before any intimal damage has healed 
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efficacy of antiplatelet therapy in maintaining vascular 
patency. There are 31 RCTs in total investigating the use of 
aspirin plus dipyridamole, or aspirin alone, in the 
comparison with the control group. The trials compare three 
treatments A (aspirin plus dipyridamole), B (aspirin only) 
and C (control group), where 6 trials (1-6) compare A, B and 
C, 4 trials (7-10) compare A and B, 13 trials (11-24) 
compare A and C and 7 trials (25-31) compare Band C. The 
data is shown in Table (2).  
2.1. Models  
  For convenience, we partition the data set into four 
groups. Let G1 = {1,…,6}, G2 = {7,…,10}, G3 = {11,…,24} 
and  G4  = {25,…,31}  be four sets of studies comparing 
treatment A versus B versus C, A versus B, A versus C and 
B versus C, respectively. Let riA, riB and riC be the numbers 
of patients that have reocclusions on treatments A, B and C 
respectively where the ith study is in G1  G2  G3, G1  G2 
 G 4 and G1  G 3  G 4, respectively, where ‘’ stands for 
‘and’. The total numbers of patients are niA, niB  and  niC, 
respectively. Let iA,  iB  and  iC  be the probabilities of 
patients that have reocclusions on treatments A, B and C 
respectively in the ith study. The riA, riB  and  riC  are thus 
binomially distributed as Bin(iA, niA), Bin(iB, niB) and 
Bin(iC, n iC) respectively. Suppose that XiA, XiB and XiC are 
the empirical logistic transforms, called the empirical log-
odds for (riA, niA), (riB, niB) and (riC, niC) respectively, where 
for example the empirical logistic transform of XiA is defined 
by log(riA +0.5)/(niA  riA + 0.5) (we may also use notation ln 
(·) here) where i is in the set G1  G 2  G 3. From Cox and 
Snell [7, page 31], if riA is not too small or not too close to 
niA, the empirical logistic transform XiA has an approximation 
normal distribution with mean log(iA/(1    iA)). The 
variance can be estimated from the data      
iA
2   = (niA+1)/((riA 
+0.5)(niA  r iA +0.5)). It iA is the same for XiB and XiC. The 
models on the log-odds scale for each group are defined as 
follows  
   
i G1,
XiC =i +iCiC,
XiA =i +i,AC +iAiA,
XiB =i +i,BC +iBiB,


	 	

	
	
 
   
i G2,
XiB =i +iBiB ,
XiA =i +i,AB +iAiA,


	
 	
 
   
i G3,
XiC =i +iCiC,
XiA =i +i,AC +iAiA,


	
 	
 
   
i G4,
XiC =i +iCiC,
XiB =i +i,BC +iBiB.


	
 	
 
  The above models are called empirical log-odds models. 
The 
   iA
2 ,
 
   iB
2  and    iC
2  are the variances of empirical log-
odds  XiA,  XiB and  XiC, respectively. The iA,  iB and  iC are 
independent and follow the standard normal distribution and 
correspond to the random sampling errors of the models XiA, 
XiB  and  XiC  within the ith study respectively. All random 
sampling errors are therefore independent and normally 
distributed as N(0, 
   iA
2 ),  N(0, 
   iB
2 )
  and  N(0, 
   iC
2 ), 
respectively. The i,AC,  i,BC  and  i,AB  are the treatment 
effects, which are defined, for example  
   
i,AC = log
iA
1iA
log
iC
1iC
. 
  It is called log-odds ratio between treatment A  and 
treatment C, measuring the effect of treatment A comparing 
to the control group C. This is the parameter of interest. The 
main purpose of the meta-analysis is to find the overall 
estimates of the log-odds ratios between treatments A versus 
C, B versus C and A versus B. We may assume a fixed effect 
or a random effect. The fixed effect model assumes that all 
the i,AC’s are the same as AC, where AC is a fixed treatment 
effect between the treatment A and the control group C for 
all studies in G1 and G3.The fixed treatment effect BC can be 
considered in the same way. It is important to note that the 
treatment effect i,AB  or its fixed effect AB  is not a free 
parameter since AB = AC  BC.  
  To address the problem of between-study heterogeneity, 
we usually use a random effect model, i.e. assume i,AC, i,BC 
and  i,AB  are random variables. If we use a normal 
distribution, the random effect model is to assume that the 
treatment effects i,AC, i,BC and i,AB are normally distributed 
as N(μAC,      AC
2 ), N(μBC,      BC
2 ) and N(μAC μBC,    AB
2 ), respec-
tively. For the studies involved in G1, the treatment effects 
i,AC  and  i,BC  are defined based on the same baseline 
treatment C and therefore may be dependent. Let  be the 
correlation coefficient between the treatment effects i,AC and 
i, BC, we may define a model as 
   
i,AC
i,BC

 

	  ~ N μAC
μBC

 

	  ,
 AC
2
 AC BC
 AC BC
 BC
2





	







	


.   (1)  
 The  parameters  μAC and μBC are the overall mean effects 
between the control group C and the treatment A, and the 
control group C and the treatment B, respectively. The 
   
 AC
2  
and      BC
2   measure the between-study heterogeneity of the 
treatment effects i,AC and i,BC, respectively. The correlation 
coefficient    measures the amount of linear association 
between i,AC and i,BC.In group G2, treatments A and B are 
involved. From (1), we have  
   
i,AB =i,AC i,BC ~ N(μAC  μBC, AB
2 ),  (2) 
where      AB
2   = 
    AC
2   + 
    BC
2     2ACBC. The entries on the 
diagonal of the covariance matrix in (1) are often called the 
heterogeneity parameters of the treatment effects in a meta-
analysis. The useful property of the model parame terisation 
is the correlation structure of the covariance matrix. An 
important special case is that the heterogeneity parameters of 
the treatment effects are assumed to be the same, i.e. AC = 
BC  =  AB, called homogeneity of variances. Hence the 
correlation coefficient   takes the value 1/2 because the 
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in the same way. A general model is to allow the 
heterogeneity parameters of the treatment effects to be 
different for each treatment effect related to the control 
group, called heterogeneity of variances.The covariance 
matrix will be in the standard form as shown in (1) and (2). 
 The  i in each group is the trial effect. We can consider 
the following two assumptions. The first one is that the trial 
effects are assumed to be study-level effects, which means 
the i’s are different fixed parameters. We need to include 31 
different unknown parameters in the model. The second one 
is that we may assume a model for i’s. A special case is to 
assume that all trial effects are the same:  = 1 = 2 = … = 
31. Conversely if the trial effect is assumed to be a random 
effect, we may assume that i  N(μ0,  
2 ) where μ is the 
overall mean of the trial effects and   measures the 
magnitude of the variation between the studies. The standard 
random effect model used in meta-analysis was described by 
[12]. To capture skewness and heavy tails in the distribution 
of the trial effect, we may use a mixture of normal 
distributions [13]. However, in practice the trial effects in 
most meta-analysis would not satisfy any model since 
different experiment designs and different data analysis 
models are used in different studies. Most of the existed 
methods therefore used the first assumption. Note that the 
number of unknown parameters is the same as the number of 
studies. This will result in some theoretical and 
computational problems. The accuracy of the estimation 
depends on the sample size of each study not the overall 
sample size of the pool in the meta-analysis. The estimates 
of some parameters may not be consistent. Due to the large 
number of parameters, the computation is usually unstable. 
We therefore propose the following empirical log-odds ratio 
model. Based on the empirical log-odds models, a model on 
the log-odds ratio scale is suggested here. Let Yi, AC = XiA  
XiC, Yi, BC = XiB  XiC and Yi, AB = XiA  XiB, which are called as 
the empirical log-odds ratio for XiA versus XiC, XiB versus XiC, 
and XiA versus XiB, respectively. The models on the log-odds 
ratio scale in each group can be defined as follows 
   
i G1,
Yi,AC =i,AC +i,ACi,AC,
Yi,BC =i,BC +i,BCi,BC,



 
 (3) 
   
i G2, Yi,AB =i,AB +i,ABi,AB,  (4) 
   
i G3, Yi,AC =i,AC +i,ACi,AC,  (5) 
   
i G4, Yi,AB =i,BC +i,BCi,BC. (6) 
  The above models are called empirical log-odds ratio 
models. The trial effect i’s are no longer in the above 
models. Note that the models Yi,AC and Yi,BC for the studies in 
G1 are not independent. The treatment effects i,AC and i,BC 
are jointly normally distributed as shown in (1). The 
   
i,AC
2 , 
   
i,BC
2  and 
   
i,AB
2   are variances of the log-odds ratios Yi,AC, 
Yi,BC  and  Yi,AB  respectively, which can be calculated from 
   iA
2 , 
   iB
2  and    iC
2   by for example 
   
i,AC
2 =
   iA
2  +    iC
2 . 
Consequently the empirical log-odds ratio models (Yi,AC, 
Yi,BC)
t for studies in G1 is distributed as  
   
N μAC
μBC

 

	  ,
 AC
2 +i,AC
2
 AC BC +iC
2
 AC BC +iC
2
 BC
2 +i,BC
2





	







	


. (7)   
 The  μAC  and  μBC  are the overall mean effects for the 
models Yi,AC and Yi,BC. The variances of the models Yi,AC and 
Yi,BC are     AC
2   + 
   
i,AC
2  and     BC
2   + 
   
i,BC
2  respectively. The 
covariance between both models is AC  BC  +     iC
2 .
 
Additionally the empirical log-odds ratio models for G2, G3 
and G4 are normally distributed as N(μAC  μBC,     AB
2 ), N(μAC, 
    AC
2 ) and N(μBC,     BC
2 ), respectively.  
2.2. Estimation  
  To make inference, the maximum likelihood method is 
applied to estimate the unknown parameters in the empirical 
log-odds ratio models given in (3)-(6). Our aim is to estimate 
the unknown parameters for the meta-analysis consisting of 
31 studies. Let  be the collection of all unknown parameters 
for the meta-analysis. Suppose that   can take any value 
within admissible ranges . The method of maximum 
Table 1.  Results for the Empirical Log-odds Ratio Models  
 
AB  AC  BC 
Model 
μAB  AB  μAC  AC  μBC  BC 
Model 1  0.108146  0.275320  -0.568930  0.275320  -0.677076  0.275320 
(SD) (0.156391)  (0.136747)  (0.161554)  (0.136747)  (0.150660)  (0.136747) 
OR scale  1.142110  1.316952  0.566130  1.316952  0.508100  1.316952 
Model 2  0.064521  0.09338  -0.599244  0.333440  -0.663766  0.318274 
(SD) (0.053287)  (0.065361)  (0.171172)  (0.228035)  (0.187616)  (0.204939) 
OR scale  1.066648  1.097879  0.549226  1.395761  0.5149085  1.37475 
Model 3  0.062605  0.00000009  -0.590714  0.335648  -0.653320  0.212374 
(SD) (0.252691)  (0.324800)  (0.262792)  (0.502075)  (0.241205)  (0.218013) 
OR scale  1.064607  1.0  0.553931  1.398847  0.520315  1.23661 Meta-Analysis of Multi-Arm Trials Using Empirical Logistic Transform  The Open Medical Informatics Journal, 2008, Volume 2    115 
likelihood is to find the value  ˆ  within  which makes the 
likelihood function of   as large as possible. The log-
likelihood function for the empirical log-odds models can be 
written as  
   
l() = log p(Yi,AC,Yi,BC |
iG1
 )+ log p(Yi,AB |)
iG2

+ log p(Yi,AC |)+
iG3
 log p(Yi,BC |)
iG4
 .
 
 Notice  that  the  l() is a summation of log-likelihoods 
from G1  to G4.The p(Yi,AC, Y i,BC |i), p(Yi,AB|i), p(Yi,AC |i) 
and p(Yi,BC |i) represent the joint probabilities or likelihoods 
of observing the data that has been collected in G1, G2, G3 
and G4 respectively. Maximizing the log-likelihood function, 
we use the function nlme  in the software R to solve the 
unknown parameters. As described in the previous section, 
there are two assumptions of heterogeneity parameters: 
homogeneity and heterogeneity variances. For the model 
with homogeneity variances (Model 1 in Table 1), we 
assume that AC = BC  =  AB and the correlation coefficient 
between the treatment effects takes 1/2. For the model with 
heterogeneity variances (Model 2 in Table 1), the correlation 
coefficient is an unknown parameters. Thus, the  in Model 
1 is {μAC,  μBC,  
2}
  while    in Model 2 is {  μAC,  μBC, 
    AC
2 , BC
2 .}and     AB
2  is given in (2).  
2.3. Numerical Results  
  The estimates of unknown parameters in Model 1 and 
Model 2 are shown in (Table 1). From Model 1, the overall 
means of treatment effects A versus B, A versus C and B 
versus C are 0.108146, -0.568930 and -0.677076 
respectively and the variation between studies in those 
comparisons are assumed the same, 0.275320. The overall 
Table 2.  Randomized Trials of Aspirin Data  
 
Study Number  Aspirin + Dipyridamole  (A) 
event/total 
Aspirin (B)  
event/total 
Control (C)  
event/total 
1 15/49  10/47 18/51 
2 35/162  37/155  47/153 
3 83/368  85/373  114/371 
4 23/100  16/100  39/100 
5 6/16  2/16 12/17 
6 0/100  6/100  12/100 
7 20/60  22/64   
8 26/313  27/317   
9 10/41  6/40   
10 8/55  15/55   
11 33/160    37/160 
12 37/202    81/205 
13 4/18    9/30 
14 17/62    20/63 
15 8/61    24/64 
16 13/47    27/46 
17 21/34    14/35 
18 11/72    15/68 
19 6/187    13/189 
20 86/286    86/263 
21 4/33    15/32 
22 15/50    12/50 
23 7/22    19/31 
24 15/132    13/67 
25   15/71  16/71 
26  6/29  15/31 
27  7/68  17/69 
28   24/215  47/213 
29   19/148  28/150 
30  6/19  18/25 
31  2/47  11/45 116    The Open Medical Informatics Journal, 2008, Volume 2  Chootrakool and Shi 
means estimated from Model 2 are quite similar. Those 
means for Model 2 are 0.064521, -0.599244 and -0.663766, 
and the variation between studies are 0.09338, 0.33440 and 
0.318274 respectively. The correlation coefficient in Model 
2 is 0.96. Notice that the estimator of  is quite close to one 
and AB is very small. All treatment effects are on the log-
odds ratio scale. In term of interpretation, we consider the 
overall means on the odds ratio (OR) scale. The results 
obtained from both models are quite close. They indicate that 
both treatment A and treatment B reduce the rates of 
reocclusion significantly by about 40% comparing to control 
group. However, the difference between treatment A and 
treatment B is neglect although treatment B is even slightly 
better than treatment A (improve by about 14% using Model 
1 and 6% using Model 2). In both models, we used empirical 
log-odds ratio models to eliminate the nuisance parameters 
(trial effects). The computation is very efficient and very 
stable, it converges very fast for almost any starting points.  
3. CONCLUSION  
  We demonstrated a normal approximation model based 
on empirical logistic transform to multi-arm trials data. The 
approximation is usually quite good if the number of 
observations in each study is not too small (the number of 
samples in a single study should usually be larger than 20). 
Since the normal distribution is used, the calculation from 
the normal approximation is much faster than from the 
model with exact binomial distributions. It takes just about 2 
seconds using Model 1 for the example discussed in this 
paper, but it takes about 30 minutes if we use the exact 
binomial distributions and conditional likelihood approach 
(it takes about 5 minutes if an unconditional likelihood 
approach is used, but this method needs to estimate s’s). 
The final results from both models are very close.  
  The estimation of   is quite trick. In our example, the 
information for  or AB mainly comes from G2.Due to small 
number of studies involved in G2, we should be careful to 
explain the values of the estimates, which  is quite close to 
1 and  is quite close to zero. In this case, a way is to assume 
the between-study heterogeneity 
    AB
2  of indirect comparison 
was not relatively estimated from the between-study 
heterogeneities 
   
 AC
2 or BC
2 ()  of the direct comparison. This 
is the Model 3 given in Table 1, which AB is an independent 
unknown parameter and   is assumed as 1/2. The results 
from Models 2 and 3 are almost the same. Several authors 
[4, 6] pointed out in the same way. Whenever there is no or 
insufficient evidence on direct comparison from RCTs, the 
indirect comparison may provide useful or supplementary 
information on the treatment effect. However the validity of 
the indirect comparisons depends on the internal validity and 
similarity of the included studies (see [6]). If the trial effects 
in the empirical log-odds model are assumed to be study-
level fixed effects, the estimation is not simple as many 
parameters are involved in the model. This leaded to a 
problem of inconsistent estimate. Solving the problem of the 
trial effect, the empirical log-odds ratio model was suggested 
in order to eliminate the trial effect from the model. Some 
other methods can also be used to address the problem, for 
example, a conditional approach based on the binomial 
distribution. We will not discuss the details here.  
  ATC(II) Collaboration [8] concluded that antiplatelet 
therapy (aspirin plus dipyridamole (A) or aspirin alone (B)) 
produced a highly significant (2p   0.00001) reduction in 
vascular occlusion in a wide range of patients. The odds of 
vascular graft or arterial occlusion were reduced by about 
40% while treatment continued. Our numerical results in the 
previous section are similar to the conclusion from [8].  
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